Navigation Links
Using Product Marketing to Launch Drugs That Outperform the Competition
Date:1/17/2008

CHAPEL HILL, N.C., Jan. 17 /PRNewswire/ -- With so much riding on new product development and market launch, the pharma industry is continually seeking to improve the expensive and time-consuming process. To launch drugs that outperform the competition, leading firms are focusing more marketing resources on the early stages of development, according to research from benchmarking leader Best Practices, LLC.

For instance, while many companies limit marketing spending in early stages to 10 percent of total pre-launch spending, organizations with consistently high product performance reported early stage spending levels as high as 27 percent, according to the study.

"Early marketing insights pay off at launch," said Cameron Tew, senior manager of research and publishing at Best Practices, LLC. "Companies that have achieved faster and higher sales uptake with new products are committing sufficient marketing resources as early as the pre-clinical phase."

The 169-page report, "Launching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters," includes 96 best practices drawn from surveys and interviews with 24 executives at more than 15 leading pharmaceutical and biotechnology companies such as Pfizer, Merck, Sanofi-Aventis, GlaxoSmithKline, Eli Lilly, Amgen, Boehringer-Ingelheim and Novartis.

For a complimentary download of a study excerpt, visit http://www3.best-in-class.com/rr900.htm .

Marketing and branding decision-makers can use the report to gather insights on development topics ranging from marketing investment and expense patterns to thought leader development for high-potential products. In addition, the report includes marketing success stories for 16 of the world's top selling drugs.

Some of the study findings include:

-- Companies that consistently launch blockbuster drugs foster a culture

that actively supports productive medical and marketing collaborations.

-- Top-performing benchmark partners conduct a wide spectrum of market

research, from pre-clinical to post-launch.

-- Leading companies spend gradually and selectively on high impact pre

marketing activities to create awareness, demand and preferences for

their new products.

To learn more about this study, review a complimentary report summary at http://www3.best-in-class.com/rr900.htm .

To drill down on the metrics and best practices presented in this report, contact Cameron Tew at 919-767-9246 or ctew@best-in-class.com .

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a research and consulting firm that conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more information, call (919) 403-0251 or visit http://www.best-in-class.com .


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Holiday Visits Nudge Many Towards Senior Housing Decision
2. Researchers seek to make cavity-causing bacteria self-destruct
3. Winemaking waste proves effective against disease-causing bacteria in early studies
4. Novare Announces Completion of 100th Single Port Laparoscopic Procedure Using RealHand(R) High Dexterity (HD) Instruments
5. Using Early Stage Commercialization Activities to Build Long-Term Success for the Bottom Line
6. Reserve 2008 Budget for Using Quality to Improve the Customer Experience
7. Older Diabetics Using Avandia Face Increased Death Risk
8. Federal Judge Says Sugar Association Suit Accusing Johnson & Johnson of False Advertising to Go Forward
9. UCSF Medical Center using newest high-tech tool for brain disorders
10. Mini transplant patients outcomes similar using related and unrelated donor cells
11. Amneal Receives FDA Approval for Bethanechol Chloride Tablets, USP Using New Expedited FDA Approval Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology: